A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Haematologica

Volumn 100, Issue 2, 2015, Pages 231-237

  Lancet, Jeffrey E ^a   Roboz, Gail J ^b   Cripe, Larry D ^c   Michelson, Glenn C ^d   Fox, Judith A ^d   Leavitt, Richard D ^e   Chen, Tianling ^d   Hawtin, Rachael ^d   Craig, Adam R ^d   Ravandi, Farhad ^f   Maris, Michael B ^g   Stuart, Robert K ^h   Karp, Judith E ⁱ  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Sunesis Pharmaceuticals Inc   (United States)

^e PharmaPacific Inc   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Rocky Mountain Blood and Marrow Transplant Program   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CHECKPOINT KINASE 2; CYTARABINE; DNA DEPENDENT PROTEIN KINASE; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BLOOD CELL COUNT; BLOOD SAMPLING; CONTINUOUS INFUSION; DIARRHEA; DNA DAMAGE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOKALEMIA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; RELAPSED ACUTE GRANULOCYTIC LEUKEMIA; SEPSIS; STOMATITIS; TREATMENT RESPONSE; WESTERN BLOTTING;

EID: 84964296859     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.114769     Document Type: Article

References (20)

1. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969-1978.
2. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989;7(8):1071-1080.
3. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma. 2002;43(9):1715-1727.
4. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062.
5. Estey EH, Kantarjian HM. Therapy for acute myeloid leukemia. In: Hoffman R, Benz Jr EJ, Shattil S, et al., eds. Hematology: Basic Principles and Practice. Philadelphia: Churchill Livingstone; 2004:1099-1120.
6. Eisenbeis C F, Larson RA. Chemotherapy of acute leukemias in adults. In: Perry MC, ed. The Chemotherapy Source Book. Philadelphia: Lippincott Williams and Wilkins; 2001:824-838.
7. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154-1163.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: acute myeloid leukemia. v2. 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed August 16, 2012.
9. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331 (14):896-903.
10. Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One. 2010;5(4): e10186.
11. Evanchik MJ, Allen D, Yoburn JC, Silverman JA, Hoch U. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiaz olyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos. 2009;37(3):594-601.
12. Walsby EJ, Coles SJ, Knapper S, Burnett AK. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 2011;96(3): 393-399.
13. Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009;64(1):53-65.
14. Hirte HW, McGuire III WP, Edwards RP, et al. Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer. J Clin Oncol. 2010;28(15s): (suppl; abstr 5002).
15. Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011;25(12):1808-1814.
16. Scatena CD, Kumer JL, Arbitrario JP, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010;66(5):881-888.
17. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.
18. Giles F, Vey N, DeAngelo D, et al. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009;114(19):4027-4033.
19. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012;30(20):2492-2499.
20. Mehta CR, Michelson G, Salganik M, et al. Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia [abstract]. J Clin Oncol. 2011;29(suppl): Abstract TPS201.